COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Evaluating Subjective Well-being in Schizophrenic Patients Treated With quetiapineXR® and Other Atypical Antipsychotics (Xperience)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00689325
Recruitment Status : Completed
First Posted : June 3, 2008
Last Update Posted : October 27, 2010
Information provided by:

Brief Summary:
To evaluate the QOL (subjective effectiveness) in patients with schizophrenia, treated with atypical antipsychotics.

Condition or disease

Layout table for study information
Study Type : Observational
Actual Enrollment : 158 participants
Time Perspective: Prospective
Official Title: A Non-interventional Study Evaluating Well-being/Quality of Life in Schizophrenic Patients Treated With Seroquel XR® (Quetiapine) and Other Atypical Antipsychotics.A 9-month, Observational, Multicentric Prospective Study.
Study Start Date : April 2008
Actual Primary Completion Date : January 2010
Actual Study Completion Date : January 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia

Primary Outcome Measures :
  1. Subjective Wellbeing under Neuroleptics' SWN-K-score; Change from baseline of QoL assessed by the SWN-K after 9 months of treatment with atypical antipsychotics. [ Time Frame: At baseline (Visit 1), and after ~3 months, ~6 months, ~9 months after V1, or at premature discontinuation ]

Secondary Outcome Measures :
  1. Positive And Negative Syndrome Scale-PANSS-8score [ Time Frame: At baseline (Visit 1), and after ~3 months, ~6 months, ~9 months after V1, or at premature discontinuation ]
  2. Global Assessment of Functioning 'GAF' scale [ Time Frame: At baseline (Visit 1), and after ~3 months, ~6 months, ~9 months after V1, or at premature discontinuation ]
  3. Disease insight; G-12 item of PANSS [ Time Frame: At baseline (Visit 1), and after ~3 months, ~6 months, ~9 months after V1, or at premature discontinuation ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with schizophrenia treated with atypical antipsychotics (AAPs) to stay in remission

Inclusion Criteria:

  • Diagnosis of schizophrenia
  • Treatment with one atypical antipsychotic* (for a first/new episode or a switch of therapy) for at least 2 weeks and maximum 8 weeks prior to the first study visit.
  • Patient takes an AAP according to local SPC and current medical practice
  • The patient must be able to understand and comply with the study requirements as judged by the investigator, e.g. patient must be able to read and write

Exclusion Criteria:

  • Treatment with an additional AAP or AP to the initial prescribed AAP within the 2-8 weeks before the patient is included in the study
  • Since the use of clozapine is limited, due to, among other things, the risk for agranulocytosis, patients on treatment with this '2nd line'AAP are excluded.
  • Previous enrolment or treatment in the present NIS
  • Known allergy to the prescribed AAP or any of its substances

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00689325

Layout table for location information
Research Site
Alphen, Netherlands
Research Site
Amersfoort, Netherlands
Research Site
Amstelveen, Netherlands
Research Site
Amsterdam, Netherlands
Research Site
Arnhem, Netherlands
Research Site
Bennebroek, Netherlands
Research Site
Boxmeer, Netherlands
Research Site
Breda, Netherlands
Research Site
Doetinchem, Netherlands
Research Site
Echt, Netherlands
Research Site
Enkhuizen, Netherlands
Research Site
Enschede, Netherlands
Research Site
Haarlem, Netherlands
Research Site
Halsteren, Netherlands
Research Site
Helmond, Netherlands
Research Site
Heythuizen, Netherlands
Research Site
Hoorn, Netherlands
Research Site
Kerkrade, Netherlands
Research Site
Kloetinge, Netherlands
Research Site
Leeuwarden, Netherlands
Research Site
Maastricht, Netherlands
Research Site
Nijmegen, Netherlands
Research Site
Oegstgeest, Netherlands
Research Site
Raalte, Netherlands
Research Site
Roermond, Netherlands
Research Site
Rotterdam, Netherlands
Research Site
Sluis, Netherlands
Research Site
Tiel, Netherlands
Research Site
Tilburg, Netherlands
Research Site
Utrecht, Netherlands
Research Site
Veenendaal, Netherlands
Research Site
Venray, Netherlands
Research Site
Vlaardingen, Netherlands
Research Site
Weert, Netherlands
Research Site
Zaandam, Netherlands
Research Site
Zoetermeer, Netherlands
Research Site
Zwolle, Netherlands
Sponsors and Collaborators

Layout table for additonal information
Responsible Party: Hans Eriksson, Medical Science Sr Director, AstraZeneca, Medical Science, Wilmington USA Identifier: NCT00689325    
Other Study ID Numbers: NIS-NNL-SER-2008/1
First Posted: June 3, 2008    Key Record Dates
Last Update Posted: October 27, 2010
Last Verified: October 2010
Keywords provided by AstraZeneca:
subjective well-being and effectiveness
Quality of Life
Additional relevant MeSH terms:
Layout table for MeSH terms
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs